RLAY

Relay Therapeutics, Inc.

September 23, 2026 · intraday

Rarity

1.69

Peak move

−10.75%

Float cap

$2.5B

Relay Therapeutics is a clinical-stage, small-molecule precision medicine company developing therapies for patients with cancer and genetic disease. Its Dynamo platform integrates computational and experimental approaches to drug protein targets previously intractable or inadequately addressed. It is advancing product candidates including zovegalisib for PI3Kα-mutated breast cancer and vascular anomalies, plus programs in NRAS-mutated solid tumors and Fabry disease.

• Key eventequity_offeringSep 23

  Relay Therapeutics announced a secondary public offering of its common stock that, including a purchase option for the underwriters, could exceed $200 million, following positive Phase 2 zovegalisib vascular-anomalies data.

  Webtheglobeandmail.com
• Key eventanalyst_ratingSep 23

  Barclays analyst Peter Lawson raised his price target on Relay Therapeutics to $27 per share from $21, maintaining a buy rating.

  Webtheglobeandmail.com
• Key eventpeer_disclosureSep 22 · 09:51 ET

  X-Chem announced a milestone under its Research Collaboration and License Agreement with Relay Therapeutics following Relay's initiation of a Phase 3 trial of zovegalisib (RLY-2608), a PI3Kα inhibitor originally identified through an X-Chem DNA-encoded chemical library screen.

  Webmanilatimes.net
• analyst_ratingSep 22

  JonesTrading analyst Boris Peaker maintained a Buy rating on Relay Therapeutics with a $20.00 price target on September 22, 2026.

  Webstockanalysis.com